



Quality end-of-Life cancer care: An overdue imperative



Guy B. Faguet^{*,1}

Retired Professor of Medicine, Hematology/Oncology, Medical College of Georgia – Georgia Regents University, Former (or Retired) Director, Cancer Immunology & Flow Cytometry Laboratories, VA Medical Center, Augusta, GA, United States

Contents

1. Introduction.....	69
2. Data sources, review of the literature, and discussion.....	70
3. An evidence-based EOL care strategy.....	70
4. Summary and recommendations.....	71
Conflict of interest.....	72
Acknowledgements.....	72
References.....	72

ARTICLE INFO

Article history:

Received 27 June 2016

Received in revised form 2 October 2016

Accepted 26 October 2016

Keywords:

Cancer

End-of-life

Quality of life

Palliative care

Dying with dignity

ABSTRACT

This review assesses the current status of end-of-life care based on large-scale, multiyear nationwide surveys of treatment modality, setting, and cost of care during terminal patients' last months of life. It shows that end-of-life care goals often remain suboptimal. Contributing factors include prioritized life preservation, uneven commitment to palliative care, few palliative care specialists, and perverse financial incentives that encourage costly interventions. Although not determinant per se, these factors coupled to doubts about what constitutes end-of-life can lead to overextended disease treatment and a late implementation of palliative care. In order to bridge the existing gap between care received and care expected and achieve quality end-of-life and promote death with dignity, we propose both to view the person rather than the disease as the unit of care and a pragmatic definition of end-of-life. Such a strategy should facilitate selecting an optimal time to transition from disease-targeted treatment to palliative care.

© 2016 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

In recent decades, enormous progress has been achieved in our knowledge of cancer at all levels. In the area of therapeutics, for instance, our armamentarium now ranges from chemotherapy drugs, to targeted agents, to immunotherapeutic approaches, to vaccines. Since 2005, FDA has approved over 60 new anti-cancer agents and expanded the indications for many others, greatly widening the range of tools to treat most cancers. Thanks to this wide choice at our disposal, patients with advanced-stage cancer of the types known to be curable are vigorously treated with specific regimens likely to achieve that goal (Faguet, 2005). Patients

with advanced-stage cancer of the types known to be incurable but responsive to treatment are offered regimens with the best risk-benefit ratio and tolerable side effects, in hopes of controlling disease progression and prolonging survival. Patients, whose tumors fail to respond to such first-line regimens, progress during treatment, or relapse after an initial tumor response, are usually treated with second-line regimens often followed by salvage-therapy without meaningfully altering the course of the disease in most cases. Such emphasis on disease control stems from both a desire to optimize each patient's prospects of achieving the best possible outcome and a reluctance to give up despite setbacks hoping the next treatment regimen might succeed where the previous one failed. However, while curative in some cases and prolonging survival of many others, extending this approach to the end-of-life (EOL) seldom achieves EOL care goals (Foley and Gelband, 2001). Factors that contribute to an over-extended focus on the disease include prioritizing life prolongation or preservation, caregivers' inadequate palliative care skills, insufficient number of palliative

* Corresponding author. Present address: 2 Oceans West Blvd, #1705, Daytona Beach Shores, FL 32118, United States.

E-mail address: faguet@yahoo.com

¹ Website: www.faguet.net.




Fig. 1. Cancer care costs during the last 6 months of life: by category.

care specialists, and perverse financial incentives that encourage costly interventions (Institute of Medicine, 2014). In the absence of a clear understanding of when a patient reaches EOL, these dynamics can lead to the protracted aggressive management of terminal cancer patients using invasive procedures with palliative care being relegated to the last few days of life. Such an EOL care strategy is ineffective, costly, detrimental to QOL, and often in conflict with patients' needs and preferences. Although adoption of palliative and hospice care has progressed in recent years, its outcome remains controversial. After identifying driving forces underlying the wanting status of EOL care we propose means to deliver quality EOL to the half million US cancer patients and nearly 10 million worldwide who reach EOL and die each year (National Vital Statistics Reports, 2016; World Health Organization, 2015).

2. Data sources, review of the literature, and discussion

We analyzed large-scale, multiyear nationwide surveys of treatment modality, setting, intensity, and cost of care during terminal patients' last months of life (Chastek et al., 2012; Morden et al., 2012; Obermeyer et al., 2014; Clark, 2007; Barnato et al., 2007). Our analysis covering over 1 million terminal cancer and non-cancer patients who died between 2000 and 2009, demonstrate that on the average end-of-life care goals remained unmet. For instance, in a recent study of 28,530 privately insured oncology patients conducted between July 2002 and December 2009 the mean health care cost incurred in the last six months before death was \$74,212 of which 55% (\$40,702) was for inpatient care and only 4% (\$3,256) for hospice care (Chastek et al., 2012). Acute inpatient care costs increased progressively each month, from \$1,785 on the sixth month before death to \$20,559 during the last month, or 81% of that month's total care cost (\$25,256). In contrast, hospice care costs increased from a negligible \$28 on the sixth month before death to \$2,464 in the last month of life (a paltry 9.8% of that month's total care cost). Other disease-targeted treatment costs decreased somewhat each month but persisted to the end, including chemotherapy (Fig. 1)

Likewise, a survey of EOL care delivered to 215,311 Medicare beneficiaries with cancer dying between 2003 and 2007 revealed that 10 or more physicians were involved during patients' last 6 months of life in 48.1% of cases, 64.9% were hospitalized during the last month of life, including 24.7% to ICU facilities, and 30.2% died while hospitalized (Morden et al., 2012). And, although 53.8% were enrolled in hospice care during the last month of life, the average stay was only 8.4 days. Similarly, in a more recent study involving 86,851 Medicare fee-for-service beneficiaries with poor-prognosis cancer, 60% were transferred eventually to a hospice program but the median stay was only 11 days (Obermeyer et al., 2014). Revealingly, a subset of 18,165 patients enrolled in hospice care experienced lower rates of hospitalization, ICU admissions, invasive procedures, lower total costs, and fewer (14% vs. 74%) died in hospital or nursing facilities than 18,165 matched non-hospice patients. Survival and other benefits of instituting early




Fig. 2. Acute EOL care vs. Survival: 1983–2006.

Derived from Ref. Teno et al., 2013a.

palliative care have been amply confirmed in several prospective studies including one of patients with newly diagnosed metastatic non-small-cell lung cancer randomized to receive either early palliative care along with standard oncologic care or standard oncologic care alone (Temel et al., 2010). Patients assigned to early palliative care had a better quality of life, fewer hospitalizations, were less likely to die in the hospital, fewer received aggressive EOL treatment, and on the average survived longer than those in the group that received standard oncologic care alone. Hence, the type and setting of EOL care rendered to over a third of a million terminal cancer patients from both the private and public sectors between 2002 and 2009 demonstrate that physicians utilize acute inpatient services through the EOL and call on consultants in vain efforts to prolong patients' survival while making only a token and late use of palliative care and hospice support.

Such an extended aggressive disease-focused stance, to the detriment of palliative care, also applies to terminal cancers in the young and to other terminal diseases as shown in two recent studies (Mack et al., 2015a; Teno et al., 2013a). The latter compared sites of death and types of care delivered to nearly 850,000 Medicare beneficiaries who died in 2000, 2005, and 2009 (Teno et al., 2013b). Although more Medicare beneficiaries died at home, and more received hospice care as the decade progressed, the frequency of hospitalizations and ICU stay increased over time leading an accompanying editorial to observe "the focus appears to be on providing curative care in the acute hospital regardless of the likelihood of benefit or preferences of patients. . . [suggesting] the increased availability of palliative and hospice care services does not appear to have changed the focus on aggressive, curative care. Hospice services appeared to be tagged on to the last days of life (Jenq and Tinetti, 2013)."

Indeed, if intensive acute care at the EOL is intended to prolong survival, results achieved thus far have not been encouraging. For instance, a retrospective survey of in-hospital care and ICU/CCU usage among Medicare beneficiaries during the last months of life ranked by survival status between 1978 and 2006 revealed that of approximately 2/3 of patients hospitalized during a typical month only 16.0% to 20.1% survived their first hospitalization. Out of the 20.3% to 27.0% hospitalized multiple times and out of the 26.1% to 33.1% treated in ICU/CCU settings, only 4.0% to 6.3% survived, respectively (Riley and Lubitz, 2010) (Fig. 2). Although the authors noted a statistically significant trend in the latter two categories, it lacks clinical relevance given the negligible survival rates reported and the inconsequential rise over a three decades-long observation period (Faguet and Davis, 1984).

3. An evidence-based EOL care strategy

While there is no one-size-fits-all approach to EOL care, prioritizing the individual rather than the disease at each stage of the process and recognizing when EOL begins are essential start-

Download English Version:

<https://daneshyari.com/en/article/5664174>

Download Persian Version:

<https://daneshyari.com/article/5664174>

[Daneshyari.com](https://daneshyari.com)